Your browser doesn't support javascript.
loading
Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients
Barroso-Sousa, Romualdo; Munhoz, Rodrigo R.; Mak, Milena P.; Fonseca, Leonardo G.; Fede, Angelo B. S.; Linck, Rudinei Diogo Marques; Coelho, Clovis R.; Moniz, Camila M. V.; Souza, Ciro E.; Dzik, Carlos.
Affiliation
  • Barroso-Sousa, Romualdo; Universidade de São Paulo. Faculdade de Medicina. Instituto do Câncer do Estado de São Paulo. São Paulo. BR
  • Munhoz, Rodrigo R.; Universidade de São Paulo. Faculdade de Medicina. Instituto do Câncer do Estado de São Paulo. São Paulo. BR
  • Mak, Milena P.; Universidade de São Paulo. Faculdade de Medicina. Instituto do Câncer do Estado de São Paulo. São Paulo. BR
  • Fonseca, Leonardo G.; Universidade de São Paulo. Faculdade de Medicina. Instituto do Câncer do Estado de São Paulo. São Paulo. BR
  • Fede, Angelo B. S.; Universidade de São Paulo. Faculdade de Medicina. Instituto do Câncer do Estado de São Paulo. São Paulo. BR
  • Linck, Rudinei Diogo Marques; Universidade de São Paulo. Faculdade de Medicina. Instituto do Câncer do Estado de São Paulo. São Paulo. BR
  • Coelho, Clovis R.; Universidade de São Paulo. Faculdade de Medicina. Instituto do Câncer do Estado de São Paulo. São Paulo. BR
  • Moniz, Camila M. V.; Universidade de São Paulo. Faculdade de Medicina. Instituto do Câncer do Estado de São Paulo. São Paulo. BR
  • Souza, Ciro E.; Universidade de São Paulo. Faculdade de Medicina. Instituto do Câncer do Estado de São Paulo. São Paulo. BR
  • Dzik, Carlos; Universidade de São Paulo. Faculdade de Medicina. Instituto do Câncer do Estado de São Paulo. São Paulo. BR
Int. braz. j. urol ; 40(6): 835-841, Nov-Dec/2014. tab, graf
Article in En | LILACS | ID: lil-735985
Responsible library: BR1.1
ABSTRACT
Purpose To assess the activity, safety and treatment patterns of sunitinib in patients with poor-risk metastatic renal cell carcinoma (mRCC). Materials and Methods We retrospectively reviewed the charts of poor risk patients treated with sunitinib from October 2006 to July 2013 who met the eligibility criteria. The primary endpoint was overall survival (OS). Tumor radiological response was measured according to RECIST 1.1 and adverse events (AEs) were assessed through standard criteria. Results Median OS was 8.16 months (95% CI, 5.73-10.59). Of the 53 patients included in this analysis, 9 (17.0%) achieved partial response, 12 (22.6%) had stable disease. Median treatment duration was 3.30 months (95% CI 1.96-4.63) and 26.4% of patients discontinued treatment due to toxicity. Grade 3 or higher AEs occurred in 39.6% of patients, the most common being fatigue (15.1%), neutropenia (9.5%), nausea, vomiting and diarrhea (7.5% each). Discussion Sunitinib may benefit some unselected poor-risk patients, although the rates of AEs and drug discontinuation suggest a need for careful patient monitoring. .
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: LILACS Main subject: Pyrroles / Carcinoma, Renal Cell / Indoles / Kidney Neoplasms / Antineoplastic Agents Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male Language: En Journal: Int. braz. j. urol Journal subject: UROLOGIA Year: 2014 Document type: Article Affiliation country: Brazil

Full text: 1 Collection: 01-internacional Database: LILACS Main subject: Pyrroles / Carcinoma, Renal Cell / Indoles / Kidney Neoplasms / Antineoplastic Agents Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male Language: En Journal: Int. braz. j. urol Journal subject: UROLOGIA Year: 2014 Document type: Article Affiliation country: Brazil